ISARIC CORONAVIRUS CLINICAL CHARACTERISATION CONSORTIUM (4C) MORTALITY SCORE

Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021

Retrieved on: 
월요일, 11월 22, 2021
Health, Infectious Diseases, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Patient, 2021 Essex County Council election, Government, British Thoracic Society, CEO, C-reactive protein, Death, MD, CRP, Pulmonary alveolar proteinosis, COVID-19, Nasdaq, Chief executive officer, Incidence, Nursing, United Kingdom, Randomness, Pharmaceutical industry, ISARIC Coronavirus Clinical Characterisation Consortium (4C) Mortality Score, Humanigen, Inc., ISARIC CORONAVIRUS CLINICAL CHARACTERISATION CONSORTIUM (4C) MORTALITY SCORE, HUMANIGEN, INC.

Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.

Key Points: 
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate, lenzilumab, today announced three abstracts pertaining to the potential use of lenzilumab in hospitalized COVID-19 patients will be presented at the British Thoracic Society Winter 2021 Meeting taking place Nov. 24-26, 2021.
  • The society counts more than 4,000 members comprised of doctors, nurses, respiratory physiotherapists, scientists, and other professionals with a respiratory interest.
  • The study also demonstrated significant improvement in SWOV for the predefined subgroup of subjects who received both corticosteroids and remdesivir (HR: 1.92; nominal p=0.0067).
  • Humanigen, Inc. (Nasdaq: HGEN) (Humanigen), is a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm.